Vistagen Therapeutics, Inc. (VTGN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in USD.

Revenue Quarterly

-1.2M -600K 0 600K 1.2M 1.8M Q1 '11: 733.9K Q2 '11: 399.6K Q3 '11: 584.8K Q4 '11: 352.7K Q1 '12: 554.6K Q2 '12: 316.3K Q3 '12: 2.4K Q4 '12: 469K Q1 '13: 200.4K Q2 '13: 0 Q3 '13: 0 Q4 '13: 0 Q1 '14: 0 Q4 '14: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 1.2M Q4 '17: 0 Q3 '18: 0 Q4 '18: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 0 Q2 '21: 334K Q3 '21: 313.6K Q4 '21: 441.9K Q1 '22: 354.1K Q2 '22: 358K Q3 '22: 357.9K Q4 '22: 38.9K Q1 '23: 310.1K Q2 '23: -893K Q3 '23: 180K Q4 '23: 176K Q1 '24: 177K Q2 '24: 278K Q3 '24: 411K Q4 '24: 197K Q1 '25: 84K Q2 '25: 183K Q3 '25: 234K Q4 '25: -15K Q1 '26: 244K Q2 '26: 258K Q3 '26: 303K Q4 '26: 465K Q1 '27: 1.5M Q2 '11 Q1 '13 Q4 '16 Q1 '20 Q4 '21 Q3 '23 Q2 '25 Q1 '27

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q1 '11: -461K Q2 '11: -862.1K Q3 '11: -2.5M Q4 '11: -2.7M Q1 '12: -1.6M Q2 '12: -1.8M Q3 '12: -2.9M Q4 '12: -2.8M Q1 '13: -1.7M Q2 '13: -1.7M Q3 '13: -1.9M Q4 '13: -1.5M Q1 '14: -1.3M Q2 '14: -1.2M Q3 '14: -1.4M Q4 '14: -1.1M Q1 '15: -1.3M Q2 '15: -1.1M Q3 '15: -1.1M Q4 '15: -3.3M Q1 '16: -1.8M Q2 '16: -5.4M Q3 '16: -2.1M Q4 '16: -8.5M Q1 '17: -2M Q2 '17: -3.1M Q3 '17: -2.6M Q4 '17: -2.5M Q1 '18: -2.3M Q2 '18: -5M Q3 '18: -2.9M Q4 '18: -4.1M Q1 '19: -4.2M Q2 '19: -7.4M Q3 '19: -7.2M Q4 '19: -5.7M Q1 '20: -6.2M Q2 '20: -5.4M Q3 '20: -6M Q4 '20: -3.3M Q1 '21: -3.1M Q2 '21: -3.3M Q3 '21: -5.3M Q4 '21: -6.2M Q1 '22: -7.7M Q2 '22: -12.8M Q3 '22: -10.5M Q4 '22: -16.7M Q1 '23: -19.8M Q2 '23: -17.5M Q3 '23: -9.8M Q4 '23: -12.2M Q1 '24: -7M Q2 '24: -6.8M Q3 '24: -7.9M Q4 '24: -11.4M Q1 '25: -12.1M Q2 '25: -14.2M Q3 '25: -15.1M Q4 '25: -14.5M Q1 '26: -15.8M Q2 '26: -20.1M Q3 '26: -19.5M Q4 '26: -16.7M Q1 '27: -13.3M Q2 '11 Q3 '13 Q4 '15 Q1 '18 Q2 '20 Q3 '22 Q4 '24 Q1 '27

Net Income Quarterly

-30M -15M 0 15M 30M 45M Q1 '11: -981.6K Q2 '11: -1.6M Q3 '11: -3.4M Q4 '11: -3.5M Q1 '12: -2.4M Q2 '12: -2.3M Q3 '12: -4.5M Q4 '12: -3M Q1 '13: -1.8M Q2 '13: -2M Q3 '13: -5.3M Q4 '13: -3.8M Q1 '14: 185.7K Q2 '14: -1.5M Q3 '14: 131K Q4 '14: -1.8M Q1 '15: -4.6M Q2 '15: -2M Q3 '15: -1.1M Q4 '15: -6.2M Q1 '16: -29.5M Q2 '16: -7M Q3 '16: -2.1M Q4 '16: -8.5M Q1 '17: -2M Q2 '17: -3.1M Q3 '17: -2.6M Q4 '17: -2.5M Q1 '18: -2.3M Q2 '18: -5M Q3 '18: -3M Q4 '18: -4.1M Q1 '19: -4.2M Q2 '19: -7.4M Q3 '19: -7.2M Q4 '19: -5.7M Q1 '20: -6.2M Q2 '20: -5.3M Q3 '20: -6M Q4 '20: -3.3M Q1 '21: -3.1M Q2 '21: -3.3M Q3 '21: -5.3M Q4 '21: -6.2M Q1 '22: -7.7M Q2 '22: -12.8M Q3 '22: -10.5M Q4 '22: -16.7M Q1 '23: -19.8M Q2 '23: -17.5M Q3 '23: -9.8M Q4 '23: -12.2M Q1 '24: -6.9M Q2 '24: -6.6M Q3 '24: -6.3M Q4 '24: -9.5M Q1 '25: -10.7M Q2 '25: -13M Q3 '25: -14.1M Q4 '25: -13.6M Q1 '26: -15.1M Q2 '26: -19.4M Q3 '26: -18.9M Q4 '26: -16.3M Q1 '27: -13M Q2 '11 Q3 '13 Q4 '15 Q1 '18 Q2 '20 Q3 '22 Q4 '24 Q1 '27

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q1 '11: -325.3K Q2 '11: -443.2K Q3 '11: 17.7K Q4 '11: -90.4K Q1 '12: -1.1M Q2 '12: -702.2K Q3 '12: -1.1M Q4 '12: -718.5K Q1 '13: -296.2K Q2 '13: -1.2M Q3 '13: -962.6K Q4 '13: -970K Q1 '14: -731.8K Q2 '14: -584.6K Q3 '14: -342.5K Q4 '14: -467.1K Q1 '15: -1M Q2 '15: -521.6K Q3 '15: -341K Q4 '15: -894.5K Q1 '16: -823.3K Q2 '16: -1.5M Q3 '16: -1.2M Q4 '16: -1.3M Q1 '17: -1.7M Q2 '17: -2.2M Q3 '17: -2.1M Q4 '17: -1.3M Q1 '18: -2.1M Q2 '18: -1.9M Q3 '18: -2.4M Q4 '18: -2.6M Q1 '19: -3.1M Q2 '19: -3.9M Q3 '19: -3.9M Q4 '19: -3.6M Q1 '20: -4.8M Q2 '20: -4.1M Q3 '20: -4.3M Q4 '20: -2.6M Q1 '21: -2.8M Q2 '21: 1M Q3 '21: -5M Q4 '21: -5.3M Q1 '22: -6.2M Q2 '22: -11.4M Q3 '22: -12M Q4 '22: -15.6M Q1 '23: -16M Q2 '23: -16.3M Q3 '23: -9.9M Q4 '23: -7.5M Q1 '24: -7.9M Q2 '24: -6.2M Q3 '24: -4.7M Q4 '24: -7M Q1 '25: -10.9M Q2 '25: -10.9M Q3 '25: -10.3M Q4 '25: -10.1M Q1 '26: -18.8M Q2 '26: -13.8M Q3 '26: -17.6M Q4 '26: -16.2M Q1 '27: -14.7M Q2 '11 Q3 '13 Q4 '15 Q1 '18 Q2 '20 Q3 '22 Q4 '24 Q1 '27

Free Cash Flow Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '18: -2.4M Q4 '18: -2.6M Q3 '19: -3.9M Q4 '19: -3.7M Q1 '21: -2.8M Q4 '21: -5.3M Q1 '22: -6.3M Q2 '22: -11.5M Q3 '22: -12M Q4 '22: -15.6M Q1 '23: -16.1M Q2 '23: -16.4M Q3 '23: -9.9M Q3 '18 Q3 '19 Q1 '21 Q1 '22 Q3 '22 Q1 '23 Q3 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q1 '11: 5.2M Q2 '11: 5.2M Q3 '11: 5.2M Q1 '12: 11.1M Q2 '12: 15.2M Q3 '12: 16M Q4 '12: 16.5M Q1 '13: 16.8M Q2 '13: 16.8M Q3 '13: 18.3M Q4 '13: 20.2M Q1 '14: 21.2M Q2 '14: 1.1M Q3 '14: 1.1M Q4 '14: 1.2M Q1 '15: 24.6M Q2 '15: 1.3M Q3 '15: 1.3M Q4 '15: 1.5M Q2 '16: 1.6M Q3 '16: 1.8M Q1 '22: 189.9M Q2 '22: 193.2M Q3 '22: 202.3M Q4 '22: 6.9M Q1 '23: 6.9M Q2 '23: 6.9M Q3 '23: 6.9M Q4 '23: 7.2M Q1 '24: 7.3M Q2 '24: 10M Q3 '24: 29.4M Q1 '25: 30.6M Q2 '25: 30.6M Q3 '25: 30.7M Q1 '26: 31.9M Q2 '26: 35.7M Q3 '26: 42.2M Q1 '27: 43M Q1 '12 Q2 '13 Q3 '14 Q4 '15 Q3 '22 Q4 '23 Q2 '25 Q1 '27

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q4 '11: -1.82 Q1 '12: -1.85 Q2 '12: -1.70 Q3 '12: -1.33 Q4 '12: -0.83 Q1 '13: -0.72 Q2 '13: -0.69 Q3 '13: -1.26 Q4 '13: -1.27 Q1 '14: -1.18 Q2 '14: -2.43 Q3 '15: -4.74 Q4 '15: -7.41 Q1 '16: -26.45 Q2 '16: -29.81 Q3 '16: -30.68 Q4 '16: -30.07 Q1 '17: -11.35 Q2 '17: -6.51 Q3 '17: -4.90 Q4 '17: -1.59 Q1 '18: -1.36 Q2 '18: -1.47 Q3 '18: -1.38 Q4 '18: -1.25 Q1 '19: -1.17 Q2 '19: -0.94 Q3 '19: -0.93 Q4 '19: -0.91 Q1 '20: -0.86 Q2 '20: -0.69 Q3 '20: -0.60 Q4 '20: -0.51 Q1 '21: -0.43 Q2 '21: -0.35 Q3 '21: -0.27 Q4 '21: -0.39 Q1 '22: -0.36 Q2 '22: -0.38 Q3 '22: -0.36 Q4 '22: -2.58 Q1 '23: -5.41 Q2 '23: -7.88 Q3 '23: -9.25 Q4 '23: -8.54 Q1 '24: -6.61 Q2 '24: -4.73 Q3 '24: -3.53 Q4 '24: -2.07 Q1 '25: -1.48 Q2 '25: -1.24 Q3 '25: -1.48 Q4 '25: -1.67 Q1 '26: -1.79 Q2 '26: -1.91 Q3 '26: -1.90 Q4 '26: -1.83 Q1 '27: -1.66 Q1 '12 Q1 '14 Q1 '17 Q1 '19 Q1 '21 Q1 '23 Q1 '25 Q1 '27

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.